AZ to transfer certain drug rights to Covis Pharma for $270m
AstraZeneca has announced it will transfer global rights to Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group in a $270m ...
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingExploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingExploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingHighlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement